Personalis Q4 clinical test volume up 41% QoQ; Medicare coverage secured for breast cancer

Personalis, Inc.

2025-FY EPS reported -$0.91 vs consensus -$0.30 ▼ miss (-204.3%)

Preliminary Q4 2025 revenue $17-18M; full year revenue $69-70M (2024: $84.6M).
Clinical test volume of 16,233 in FY2025, up ~400% YoY; Q4 alone 6,183 tests (+41% vs Q3).
Clinical test revenue doubled to ~$2.0M in FY2025 (2024: $0.8M).
Cash, equivalents, and short-term investments ~$240M, including $109M from ATM at $8.43/share.
Secured Medicare coverage for breast cancer surveillance, a key reimbursement milestone.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.